(Total Views: 358)
Posted On: 06/10/2025 5:47:06 PM
Post# of 154604
NCT04313075:
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
NCT04504942:
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
NCT0383867:
???...now not showing
___
We've used 28 basket" trial as total for a while, but incorrect. ESMO & BTD were based on pooled data from the 90 patients
There's more data, whichever it is, beyond the 28 ESMO poster.
Will be very interesting the # & location of all the tumors.....
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
NCT04504942:
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
NCT0383867:
???...now not showing
___
We've used 28 basket" trial as total for a while, but incorrect. ESMO & BTD were based on pooled data from the 90 patients
There's more data, whichever it is, beyond the 28 ESMO poster.
Will be very interesting the # & location of all the tumors.....
(3)
(0)
